Introduction
The accurate diagnosis of chronic hepatitis C (CHC) related fibrosis is crucial for prognosis and treatment decisions, and is currently best evaluated by histological examination of liver biopsy [1, 2] . However, liver biopsy has several disadvantages, including poor patient compliance, sampling errors, limited usefulness for dynamic follow-up, and a risk of complications typical of invasive procedures. In addition, the predictive power of histology may be weakened by sampling variability [3] [4] [5] [6] [7] . Together, these constraints of liver biopsy have encouraged the search for non-invasive methods to assess progression of fibrosis. The ideal noninvasive technique should be valid, painless, reproducible, easy-to-learn, easy-to-perform and cheap.
There is an interest in developing methods, either serological or imaging, which are all non-invasive, in order to determine the presence and degree of fibrosis. Among these new techniques are serum markers and unidimensional transient elastography (FibroScan 
Patients and Methods

Study design
This cross-sectional study was conducted at Specialized Medical Hospital and the Egyptian Liver Foundation, Mansoura, Egypt. The inclusion criteria were: age older than 18 years and chronic infection by hepatitis C, characterized by the presence of HCV-RNA in blood serum. The exclusion criteria were the presence of ascites, pacemaker or pregnancy. Three hundred and fifty six consecutive patients with chronic hepatitis C participated in the study. Therefore, 356 pairs of exams were done by two operators at the same day. Both operators have realized more than 500 exams previously, being classified as experienced operators [21] . The LSM value used in this analysis was the mean of the two readings.
Ethical Considerations
This study protocol was conducted in accordance with the Helsinki Declaration, and was approved by Mansoura Faculty of Medicine Ethics Committee. All patients signed an informed consent upon enrolment in this study.
Transient elastography (TE
The procedures were performed by two independent investigators (MA and RS) on the same day. The right lobe of the liver was accessed through an intercostal space while the patient was lying down in the dorsal decubitus position with the right arm in maximum abduction position. Using the FibroScan (Echosens, Paris, France) guide, a portion of liver of at least 60 mm in thickness, free of large vessels, was identified for examination. The rate of successful measurement was calculated as the ratio between the numbers of validated to total measurements. The results were expressed as a median value of the total measurements in kilo Pascal (kPa). TE was considered reliable when the following criteria had been met: (i) 10 successful measurements; (ii) an interquartile range (IQR) lower than 30% of the median value; and (iii) a success rate of more than 60% [22] . Liver stiffness was considered as the median of all valid measurements.
Liver biopsy
Liver biopsy specimens were obtained under complete aseptic procedures to retrieve 15 mm core or at least 15 portal tracts. The specimen was processed and stained with hematoxline and eosine. Fibrosis was staged on a 0-4 scale: F0, no fibrosis; F1, portal fibrosis without septa; F2, portal fibrosis and few septa; F3, numerous septa without cirrhosis; and F4, cirrhosis according to METAVIR scoring system [23] .
Statistical analysis
Statistical 
Results
The study included 356 patients [70.8% male gender, median (IQR) age 39 (31-47) years, BMI 27.6 (24.4-32.5) kg/m²]. Table ( 2) shows the baseline characteristics of the studied patients. Of the all studied patients; according to Metavir score, liver biopsies showed that 11 patients were scored as F0 fibrosis (3 %), 245 patients were F1 (69%), 58 (16%) of our patients were F2, 34 cases (10%) were F3 and only 8 patients (2%) were scored as F4. Liver stiffness values ranged from 3.4 to 63.9 kPa (median 7.15 kPa). The overall relation between all patients on all fibrosis stages when comparing both FibroScan and biopsy was significant agreement between both (the kappa measure was 0.430 and p<0.001). 
Discussion
In Egypt, where the HCV prevalence is the highest in the world [24] , the National recommendations required that HCV-infected patients undergo a liver biopsy at the initial evaluation and that a treatment is offered to patients with a fibrosis rate ≥F2. Having a cheaper and more acceptable alternative to liver biopsy is critical in a country where six million individuals are chronically infected with HCV [25] . However, these new noninvasive methods should be locally evaluated, as circulating virus genotype (genotype 4), increased body mass index highly prevalent in Egypt, and co-infections with schistoso-miasis may interfere with liver fibrosis assessment. The national plan of action for prevention, care and treatment of viral hepatitis in Egypt (2014-2018) suggested the use of noninvasive methods (FibroScan and FIB4) for evaluation of viral hepatitis patients [26] . The use of TE is based on establishing cutoff values for each stage of fibrosis. A diagnosis of stage F ≥2, F ≥3 and F4 (cirrhosis) is based on measurements of liver stiffness that vary, according to some studies, from 6.2 to 8.8 Kpa, 7.7 to 10.8 kPa and from 11 to 16.3 kPa (Table 1) . TE might be influenced by the etiology of liver disease [27] and the prevalence of fibrosis, known as spectrum effect [28] . These two major factors may explain the difference among these studies. Our major strength was the fact that our sample was composed exclusively by patients with chronic hepatitis C infection. Previous studies that have evaluated TE analyzed patients with chronic liver disease of mixed etiologies. Liver stiffness measurement accuracy and proposed cutoffs were different according to the liver disorder [29] . Although the agreement of fibrosis stages between TE and liver biopsy is good (ê = 0.430, p<0.001), however, we found discrepancies on studying the effectiveness of TE as a method for diagnosis of hepatic fibrosis compared to that of liver biopsies. In our study we found 256 patients with F0-1 on liver biopsy, and on FibroScan, 263 showed F0-1, 58 patients showed F2 on liver biopsy, while by FibroScan 15 cases were F2, 43 cases were F3 on liver biopsy, while 34 were F3 by FibroScan. Eight patients showed F4 on liver biopsy, while 35 patients showed F4 by Fibroscan. The areas under ROC curve for the diagnosis of fibrosis F=2, F=3 and F=4 were 0.908, 0.947 and 0.974, for the cutoff values of 9.825 kPa, 10.375 kPa and 17.225 kPa. These results suggest that FibroScan performs well in identifying cases with no or minimal fibrosis, but is less accurate in identifying higher degrees of fibrosis. This is important because F2 is a threshold for initiating treatment in many counties [10] . Perazzo et al. [30] attributed this over-estimation of liver fibrosis by TE to flare of transaminases, extrahepatic cholestasis and liver congestion, non-fasting status, and liver steatosis. Wong et al. [31] concluded that TE might overestimate liver fibrosis when ALT is elevated in cases of chronic hepatitis B or C.
Conclusion
Transient 
